Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I sequential Alluminox plus pembrolizumab for recurrent/metastatic nasopharyngeal or sinonasal squamous carcinoma
jRCTs031230728Phase 1Suspended
- Sponsor
- Rakuten Medical, Inc.
- Start
- Mar 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of pembrolizumab in nasopharyngeal carcinoma (NPC), sinonasal squamous cell carcinoma (SNSCC) and squamous cell carcinoma of the paranasal sinuses (SNSCC), sponsored by Rakuten Medical, Inc. Primary endpoint: Dose-limiting toxicity rate. Started Mar 2024; status: suspended.
02
Drugs
03
Conditions
nasopharyngeal carcinoma (NPC)sinonasal squamous cell carcinoma (SNSCC)squamous cell carcinoma of the paranasal sinuses (SNSCC)
Beyond the preview
Go deeper on jRCTs031230728.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031230728.